Our Opinion

POINT Biopharma Global Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“In animal studies PNT6555 has successfully delivered large doses of radiation to tumors while limiting dose to non-target tissues.” Read the following article

Company Description

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Company Website: https://www.pointbiopharma.com